PharmaVOICE

Abcnews | April 26, 2020

State and local governments across the United States have obtained about 30 million doses of a malaria drug touted by President Trump to treat patients with the coronavirus, despite warnings from doctors that more research is needed. At least 22 states and Washington, D.C., secured shipments of the drug, hydroxychloroquine, according to information compiled from state and federal officials by The Associated Press. Sixteen of those states were won by Trump in 2016, although five of them, includin...

PharmaTimes | January 28, 2020

The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...

GEN | April 06, 2020

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Business Insights

EyePoint Pharmaceuticals, Inc. | March 10, 2022

A pharmaceutical company, EyePoint Pharmaceuticals, Inc.dedicated to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has entered into a loan agreement with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC for senior secured credit facilities for $45 million (CRG). A $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be used to replac...